Is the semaglutide tablet as effective as the injection for weight loss?

Step 1, understand why the two forms work differently

Semaglutide is the same active molecule whether it arrives in a pen or a tablet. The difference lies in how it reaches your bloodstream. Injected semaglutide bypasses the gut entirely; nearly all of each dose gets absorbed. The tablet relies on an absorption enhancer called SNAC, which briefly raises the local pH in your stomach lining and allows a fraction of the drug through. That fraction is enough to produce significant appetite suppression, but only if the conditions are right.

This is where a common misconception tends to take hold. Many people assume that because the tablet dose (25mg) is so much higher in milligrams than the injection (2.4mg), it must be delivering more medicine to the body. In reality, the higher milligram figure compensates for lower oral bioavailability, and the two forms end up with broadly similar concentrations in the blood at maintenance, though the injection is somewhat more consistent dose to dose. If you are wondering whether oral semaglutide is as effective as the injection, the distinction matters, but it does not make the tablet ineffective.

You can read more about the full head-to-head breakdown of the tablet and injection if you want the pharmacology laid out in more detail.

Step 2, look at what the trials actually measured

Two phase-3 trials are the relevant reference points here. STEP 1 tested the 2.4mg weekly injection over 68 weeks in adults with obesity but without diabetes; participants lost an average of around 15% of their body weight, as published in the New England Journal of Medicine. OASIS 4 tested the 25mg daily tablet over 64 weeks in a similar population; the average was around 13.6% regardless of adherence, rising to approximately 16.6% among participants who stayed fully adherent throughout.

A few cautions about reading those numbers side by side. The trials ran at different durations, enrolled slightly different populations, and measured outcomes differently. No head-to-head randomised trial of the tablet against the injection has been published. What the OASIS 4 data do show clearly is that the tablet is a clinically meaningful treatment, not a diluted version of the injection. The gap between 13.6% and 15% is real but modest, and it can close considerably if the morning routine is followed consistently.

People weighing up the two options often find the practical question of injections versus tablets just as relevant as the efficacy numbers.

Step 3, factor in the practical differences that affect real-world results

Efficacy in a controlled trial and effectiveness in daily life are not always the same thing. The injection has a forgiving administration: once a week, at any time of day, with no food restrictions around it. The tablet's strict morning ritual (first thing on waking, a small amount of plain water, then a 30-minute wait before coffee, breakfast or other medicines) is straightforward for some people and genuinely difficult for others.

If the morning routine slips repeatedly, absorption drops and the clinical benefit does too. That is not a flaw in the medicine; it is the pharmacology of oral delivery. Conversely, people who find needles a barrier to starting treatment may adhere more reliably to a tablet, which could close the real-world gap. A prescriber who knows your daily routine and medical history is better placed than any article to advise which form gives you the better chance of sustained results.

The question of oral versus injected semaglutide covers the administration practicalities in full. For context on what treatment costs privately, our Wegovy tablet cost page sets out what an honest transparent price includes.

Step 4, know what both options share

Whatever the delivery route, semaglutide works as a GLP-1 receptor agonist: it signals fullness to the brain, slows gastric emptying and reduces appetite. Both the tablet and the injection carry the same general side-effect profile, dominated by gastrointestinal effects, nausea, loose stools, constipation and occasionally vomiting, most prominent when starting or moving up a dose. These effects are usually transient and taper as the body adjusts.

Both forms are Black Triangle (▼) medicines under additional MHRA monitoring, and both are prescription-only. The NHS semaglutide page covers the shared safety considerations clearly and is worth reading alongside this page. Neither form is licensed for use in pregnancy, breastfeeding, or in people trying to conceive, and both are currently for adults only. Eligibility also depends on BMI and the presence of weight-related conditions, a prescriber confirms suitability at consultation, not a number on a calculator alone.

Our weight-loss treatment overview explains where both options sit within the broader landscape of licensed medicines. If you'd like to discuss which form might suit you, a free eligibility consultation with one of our GPhC-registered prescribers is the right starting point.